46 patients with UC were included in the study. The study design was approved by a local institu tional review board.
The characteristics of the study group are pre sented in tAbLE 1. All patients underwent a com prehensive diagnostic workup to maximize the homogeneity of the analyzed group. The lab oratory panel consisted of full blood count, C re active protein, alanine transaminase, aspartate transaminase, γ glutamyl transpeptidase, alka line phosphatase (to exclude potential primary sclerotizing cholangitis), and antitissue trans glutaminase antibodies with total immunoglob ulin A count (to exclude celiac disease). Prior to endoscopic procedures, each patient provided a stool sample. In every sample, stool culture, glutamate dehydrogenase with Clostridium difficile toxin A/B and Giardia lamblia antigen tests were performed. FC levels were estimated with in 48 hours with the Quantum Blue® Calprotec tin High Range Test (BÜHLMANN Laboratories AG, Schönenbuch, Switzerland). In the first 40 patients enrolled in the study, the gold standard ELISA test was also performed (BÜHLMANN fCAL® ELISA). The range of FC values measur able by the semiquantitative Quantum Blue test ranged from 100 µg/g to 1800 µg/g (per gram of stool). Clinical disease activity was assessed us ing the Crohn's Disease Activity Index (CDAI) and the partial Mayo score.
In all 46 patients with UC and in 57 of 94 pa tients with CD, ileocolonoscopy was performed by a gastroenterology specialist. To assess the lo cation of the disease, additional gastroduodenos copy, abdominal ultrasound, or computed tomog raphy with enteroclysis were performed in pa tients with CD. Both the location and extent of the disease were established in accordance with the Montreal classification. 13 Endoscopic activi ty of UC was graded in accordance with the Mayo score.
14 In patients with CD, endoscopic disease activity was assessed using the 4 grade scoring system: Simple Endoscopic Score for Crohn's Dis ease (SES CD).
15
Statistical analysis was performed using Graph Pad Prism version 6.0 (GraphPad Software, Inc. La Jolla, California, United States). The results are expressed as the mean with SD or median with interquartile range (IQR), depending on the dis tribution. Variable distributions were tested with the Shapiro-Wilk test of normality. Bivari ate correlations were assessed with the Pearson's or Spearman's test, as appropriate. To compare clinical indices between the 2 groups, the t test was used, and if the normality test failed, the ex act Mann-Whitney test was performed. A 2 tailed P value of less than 0.05 was considered statis tically significant. To assess diagnostic accuracy of FC in disease flare detection, the receiver op erating characteristic (ROC) curve and the area under the curve (AUC) were computed. rEsuLts A total of 140 patients with IBD were included in the study (64 men and 76 women; quantitative bedside tests have been developed that may play an important role especially in the hospital setting, as the results may be ob tained already in 40 minutes. It has been proved that these rapid bedside tests highly correlate with ELISA results (87%-90%). 7, 8 On the oth er hand, whether the diagnostic accuracy of FC is equally high with different locations of dis ease is still being debated.
5,9-12 Therefore, the aim of the current study was to prospectively assess the clinical usefulness of FC measured by a rap id bedside test in the detection of IBD flares. We also analyzed the influence of disease location on the accuracy of the biomarker. In both subgroups, FC levels highly correlat ed with the endoscopic indices. In UC, median FC levels increased dynamically in the presence of a disease flare (FIGurE 2A). In patients with active In the ROC curve analysis, the calculated cut off value for FC for the detection of active lu minal CD was 238.5 µg/g, with high specificity and sensitivity (88.89% and 70.0%, respective ly), and an AUC of 0.831. For UC, the cut off val ue was higher: 499.0 µg/g, with a specificity and sensitivity of 88.89% and 60.0%, respectively, and an AUC of 0.80.
No association was found between C reactive protein, white blood cell count, and clinical activ ity indices with endoscopic scores.
The extent of inflammation and its location in the gastrointestinal tract did not affect the fi nal FC concentrations in any of the subgroups A similar relationship was found in patients with CD (FIGurE 2b) . In the presence of mild endoscopic signs of disease flare (SES CD, 4-10 points), me dian FC levels significantly increased when com pared with remission period (252.1 and 100.0 µg/g, respectively; P = 0.02). In cases of active muco sal inflammation, the median FC level was 6 fold higher compared with full endoscopic remission (643.0 µg/g [IQR, 189-1800] vs 100.0 µg/g [IQR, 100-362.5 µg/g], respectively; P <0.001). More over, endoscopy revealed active lesions in half of the patients in complete clinical remission defined by the CDAI and partial Mayo score: 66.7% and 47.1% in patients with UC and CD, respectively. coefficient (r = 0.868) that we observed is com parable to the results reported by Lobatón et al, 8 which included 115 ileocolonoscopies of pa tients with CD in clinical remission (r = 0.879, P <0.0001). 8 The most clinically significant conclusion that we can draw from our analysis is that FC lev els increase dynamically even in the presence of the mildest signs of endoscopic activity (FIGurE 2) . While the FC level remains below 100 µg/g in full endoscopic remission in UC, its value triples (323 µg/g) even with the mildest endoscopic ac tivity (Mayo score 1). Similarly, in CD, in the pres ence of mild mucosal inflammation (SES CD, 4-10 points), the FC level rises to 252 µg/g. A rel atively high specificity for the Qunatum Blue test is therefore crucial. This rapid bedside test can facilitate clinical decisions on hospital ad mission, such as deciding whether the IBD treat ment should be intensified. Similarly, in the am bulatory setting, it is crucial when determining whether a patient should undergo endoscopy or not. On the other hand, as the ultimate goal of IBD treatment is to achieve full mucosal healing, the FC test may become an easy and practical tool to monitor fully asymptomatic patients, 50% of whom have endoscopically detectable disease ac tivity (data not shown).
In previous studies that analyzed the calpro tectin cut off value for the detection of endo scopic flares in CD, 5,11,16,17 the value usually fluc tuated between 50 and 250 µg/g, depending on the adapted endoscopic criteria and activity scores (SES CD, CDEIS [Crohn's Disease Endoscopic In dex of Severity]). Our cut off value of 247 µg/g is towards the upper limit of this range, possibly because our cohort consisted of hospitalized pa tients, with some of them admitted for acute flare of CD. In the case of UC, the cut off value was ev idently higher (499 µg/g), which may be due to 2 factors. 18, 19 First, the adapted criteria for disease flare included all 3 grades of the Mayo endoscopic score, and the majority of the participants gained 2 or 3 points. This may be because physicians were directing the patients to our department when they suspected a disease flare. Second, the Quan tum Blue® method is semiquantitative and does not report results below 100 μg/g, so the final cut off value may have been overestimated.
In summary, FC levels assessed by the rapid Quantum Blue® test highly correlated with en doscopic activity scores both in UC and CD (AUC, 0.80 in UC; 0.83 in CD), rising significantly even in the presence of minor signs of inflammation. Early detection of IBD flares, even before the oc currence of clinical symptoms, may be a useful tool in everyday practice, allowing a more rap id and accurate optimization of IBD treatment.
The second aim of the study was to evaluate the effect of disease location on FC levels. Data collected in our study showed a definite lack of correlation between the location of active in flammation throughout the gastrointestinal tract and the biomarker level. Nevertheless, FC levels (FIGurE 3) . In UC, the median FC value was low er in patients with disease limited to the rec tum (E1) than in left sided colitis (E2) and pan colitis (E3), but the difference did not reach sig nificance (340.0, 500.0, and 421.5 µg/g, respec tively). In CD, a trend was observed towards lower median FC levels in small bowel disease (Montreal classification, L1) compared to ex tensive small and large bowel involvement (L3) (195.0 µg/g [IQR, 100-511.3 µg/g]) vs 591.5 µg/g [IQR, 105.5-1053 µg/g]), but the difference was not significant.
dIscussIon One of the greatest challenges in IBD treatment is to develop more precise and less invasive diagnostic tests that could be use ful in disease monitoring. Early detection of a dis ease flare can help optimize IBD care. 1,2 FC has al ready been adapted in clinical practice in West ern Europe as a surrogate marker for intestinal inflammation. It highly correlates with endoscopic scores of activity, 5, [16] [17] [18] [19] [20] and from an economic point of view, it is cheaper, faster, and more patient friendly than the standard endoscopic proce dures. This biomarker may be adapted in biolog ical therapy monitoring, which is nowadays com monly used in IBD care in Poland. [21] [22] [23] It has been shown that FC elevation predicts short term re lapse after discontinuation of antitumor necrosis factor α therapy in patients with IBD in deep re mission. 24 Moreover, in the POCER study, Wright et al 25 found that FC elevation predicted early postoperative recurrence in patients with CD.
In clinical practice, timing is crucial when mak ing therapeutic decisions for hospitalized IBD patients. As the gold standard ELISA test is per formed in the laboratory setting after at least several stool samples have been collected, a clini cian may have to wait a few days to obtain the re sults. Recently, alternative rapid semiquantitative tests that can be performed in less than 30 to 40 minutes have been developed. More important ly, testing can be performed by a nurse direct ly on the ward without special infrastructure. 7, 26 This was the rationale for conducting a prospec tive, clinically oriented study to determine how the rapid bedside FC test may be adapted to hos pital settings.
The strength of our analysis is the inclusion of a highly homogeneous group of patients with IBD. By conducting a thorough diagnostic workup, we excluded celiac disease, diverticulosis, colorectal cancer, and gastrointestinal infections (such as Clostridium difficile infection and giardiasis), that is, any gastrointestinal disorders that may simu late IBD exacerbation and influence the final re sults. 27 In addition, the highly homogenous group included more than 130 patients, a notably higher number of patients than in previous publications.
The results of our study confirm the high correlation of the Quantum Blue method with the gold standard, ELISA, which was reported in a large analytical study that showed an agreement of 89.4%. 26 Moreover, the Pearson correlation of inflammation both in UC and CD. Moreover, this test may be considered an alternative to colo noscopy because of its high correlation with en doscopic activity scores. contribution statement AM, SG, and GR designed the study. AM performed the laboratory analysis. AM, SG, and GR performed the analysis and inter preted the data. All authors contributed to draft ing the manuscript and accepted its final version.
rEFErEncEs directly correlated with the intensity of mucosal inflammation.
In patients with UC, we observed slightly low er FC levels in proctitis compared with left sided UC and pancolitis, but this finding was not sig nificant. FC values highly correlated with the Mayo endoscopic score, rising nearly arithmeti cally with the severity of inflammation and reach ing the upper limit of the Quantum Blue® test at grade 3. Presumably, FC levels increase rapid ly both in proctosigmoiditis and extensive coli tis, because the main sources of this protein are granulocytes and lymphocytes, which massive ly infiltrate the bowel wall during ac tive inflam mation. These findings partially confirm the re sults of Ricanek et al, 10 who reported no differ ence in FC levels between left sided UC and pan colitis, while showing them to be significantly lower in proctitis.
Similarly, in CD, no significant difference was found with regards to disease location. Never theless, we did observe a trend towards higher FC levels in patients with ileocecal disease. Un fortunately, we could not include the L4 local ization (upper gastrointestinal tract) in the sta tistical analysis owing to the low number of pa tients (n = 6). Previous publications in the field do not clearly answer the question as to wheth er FC can predict mucosal inflammation equally in different locations of CD. As CD can affect any segment of the digestive tract from the mouth to the anus, assessment of the location becomes more complex, and methods vary across studies. Sipponen et al 11 showed a higher FC level in co lonic than in isolated small bowel disease in 77 patients with CD. Similarly, Schoepfer et al 5 sug gested that FC was less reliable in patients with pure ileal CD, because the Spearman's rank corre lation coefficient for endoscopic activity was low er than for colonic disease (r = 0.65 vs r = 0.8).
Jensen et al
12 also included capsule endoscopy in their location assessment, showing equal ac curacy of FC in the prediction of active disease in both isolated small bowel and colonic disease in 118 patients with CD. Our analysis confirms the results of a recent study by Goutorbe et al 9 on the utility of FC in the assessment of CD ac tivity, as the authors also did not show any rela tionship between disease location and FC levels using the same Quantum Blue® method.
The most important conclusion we can draw from this subanalysis is an extremely practical aspect of FC measurement in CD monitoring, es pecially in isolated small bowel disease. Given its high diagnostic accuracy and low cost, this non invasive test should also be implemented in rou tine ambulatory practice in Poland, where access to specialist imaging methods such as computed tomography or magnetic resonance imaging en terography is very limited.
In summary, the rapid bedside FC test is an ad equate and effective alternative to the time consuming ELISA method. FC levels increase rapidly even in the presence of the mildest signs
